Association Between PD-L1 Expression and Driven Gene Status in NSCLC: A Meta-Analysis

Publication date: Available online 21 February 2017
Source:European Journal of Surgical Oncology (EJSO)
Author(s): Dianhe Li, Xiaoxia Zhu, Haofei Wang, Na Li
PurposeWe explored the potential clinical association between programmed death-ligand 1 (PD-L1) expression and driven gene status in non-small cell lung cancer (NSCLC).MethodsWe systemically searched through October 2015. Odd ratios (ORs) with 95% CIs were calculated to examine the association of PD-L1 expression with driven gene status. A random- or fixed-effects model was used.ResultsNine studies were identified. KRAS-mutant tumors were more likely to be PD-L1 positive than KRAS-wild type tumors (51% vs 36%; OR 1.69; 95% CI 1.01-2.84; p = 0.045). In contrast, PD-L1 expression did not differ by EGFR (OR 0.86; 95% CI 0.43-1.73; p = 0.675) or ALK (OR 1.02; 95% CI 0.44-2.37; p = 0.954) status. In subgroup analysis, there was also no significant association between PD-L1 expression and EGFR status in term of the cut-offs or ethnicity.ConclusionIn conclusion, NSCLC with KRAS mutations showed a trend for higher frequency of positive PD-L1 expression.



http://ift.tt/2mcDvrZ